| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| SL7-HP2H3 | Human | PE-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag (Site-specific conjugation) |  |
||
| SL7-HF2H7 | Human | FITC-Labeled Human SLAMF7 / CRACC / CD319 Protein, His Tag |  |
|
|
| SL7-R52H7 | Rhesus macaque | Rhesus macaque SLAMF7 / CRACC / CD319 Protein, His Tag (MALS verified) |  |
|
|
| SL7-M5252 | Mouse | Mouse SLAMF7 / CRACC / CD319 Protein, Mouse IgG2a Fc Tag, low endotoxin |  |
|
|
| SL7-H82E0 | Human | Biotinylated Human SLAMF7 / CRACC / CD319 Protein, Avitag™,His Tag (HPLC verified) |  |
|
|
| SL7-H5256 | Human | Human SLAMF7 / CRACC / CD319 Protein, Fc Tag |  |
|
|
| SL7-H5225 | Human | Human SLAMF7 / CRACC / CD319 Protein, His Tag (HPLC verified) |  |
|
|
1e6 of the anti-SLAMF7 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human SLAMF7, His Tag (Cat. No. SL7-HP2H3) and negative control protein respectively, PE signals was used to evaluate the binding activity (QC tested).
Immobilized Human SLAMF7, Fc Tag (Cat. No. SL7-H5256) at 2 μg/mL (100 μL/well) can bind Humanized Anti-Human CS1 MAb with a linear range of 0.3-5 ng/mL (Routinely tested).
The purity of Rhesus macaque SLAMF7, His Tag(Cat. No. SL7-R52H7) was more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Elotuzumab | PDL-063; HuLuc-63; BMS-901608 | Approved | Abbvie Inc, Bristol-Myers Squibb Company | Empliciti | Japan | Multiple Myeloma | s:28:"Bristol-Myers Squibb Company"; | 2015-11-30 | Smoldering Multiple Myeloma; Multiple Myeloma | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| CS1 Targeted CAR T-cells (Yake Biotechnology) | Phase 1 Clinical | Multiple Myeloma | Details | ||
| CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology) | Clinical | Wuhan Bio-Raid Biotechnology, Tongji Hospital | Hematologic Neoplasms | Details | |
| BCMA-CS1 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics | Multiple Myeloma | Details | |
| UCART-CS1 | UCART-38; UCART-CS1 | Phase 1 Clinical | Cellectis | Multiple Myeloma | Details |
| Anti-CD3/Anti-SLAMF7 Bispecific Antibody (University of Virginia) | Phase 1 Clinical | Multiple Myeloma | Details |
This web search service is supported by Google Inc.
A-Z